Regeneron backs $75M series A for antibody upstart Infinimmune
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Regeneron backs $75M series A for antibody upstart Infinimmune" is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.
Outlets currently covering the story include FirstWord Pharma, bizjournals.com, biopharmadive.com and Longevity.Technology. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 94d ago.
Quick answers
Why is "Regeneron backs $75M series A for antibody upstart Infinimmune" trending?
Because 7 independent news sources published 7 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- Infinimmune bags $75M for atopic dermatitis antibody duo FirstWord Pharma · 96d ago
- Alameda biotech Infinimmune scores $75 million as it plans first clinical trials bizjournals.com · 96d ago
- Chasing Dupixent, a biotech aims to make better antibody drugs for eczema biopharmadive.com · 96d ago
- Re-engineering immune memory for tissue repair Longevity.Technology · 96d ago
- Infinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease Business Wire · 96d ago
- Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M Endpoints News · 96d ago
- Regeneron backs $75M series A for antibody upstart Infinimmune Fierce Biotech · 96d ago
Topics
Related trends
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi and Regeneron have deepened their immunology alliance in a deal worth up to $8 billion to secure early-stage assets and a Dupixent successor.
Kodiak Sciences stock soars on positive AMD trial data
Kodiak Sciences shares surged over 90% following positive Phase 3 trial results for an eye disease drug targeting AMD.
The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Kodiak skyrockets on positive study data for 2 eye drugs
Kodiak stock surges after a Phase III clinical victory for its Eylea rival targeting wet AMD.
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.